Gipeun, FSN subsidiary Boosterz’s skin longevity brand, is gaining popularity.


Gipeun Neo Shot Skin Boost Serum. FSN

Gipeun Neo Shot Skin Boost Serum. FSN

View original image

According to Boosterz on November 5, its “Neo Shot Skin Boost Serum” ranked No. 1 in both the overall product rankings and the skincare category of Musinsa Beauty’s real-time rankings.


Gipeun is a skincare brand built on the philosophy of “skin longevity,” which aims to maintain the skin’s natural health over time. Its flagship product, Neo Shot Skin Boost Serum, uses Neo Shot, an ultrafine spicule technology containing PDRN and NAD. Each bottle contains a total of 10 million Neo Shot spicules.


Building on the product’s distinctive strengths, Gipeun raised more than KRW 100 million in cumulative funding in its first Wadiz crowdfunding campaign in July 2026, achieving 20,773% of its target. It has also received more than 1,900 cumulative purchase reviews across major online sales channels, including Naver Smart Store, Coupang, and Musinsa Beauty.


Boosterz plans to increase brand awareness and accelerate its global business expansion. Since October 2026, it has been running a terrestrial TV advertising campaign featuring four different ad creatives. It is also broadening consumer engagement and its sales base, focusing on major online channels such as Naver Smart Store and Musinsa Beauty. In addition, the company plans to strengthen its presence on major overseas online sales channels, including Amazon in North America and Qoo10 in Japan, and expand growth opportunities in global markets by identifying local distribution partners.



A Boosterz representative said, “Building on the consumer response and sales experience we have accumulated in Korea, we will strengthen the brand’s competitiveness in overseas markets such as North America and Japan and develop it into a growth brand in the K-beauty sector.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing